Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8%

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 1,810,000 shares, an increase of 145.8% from the January 15th total of 736,500 shares. Currently, 9.4% of the company's stock are short sold. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is presently 1.8 days.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL traded up $0.05 during trading hours on Friday, reaching $2.76. 277,465 shares of the stock were exchanged, compared to its average volume of 2,622,860. The stock's fifty day simple moving average is $2.06 and its 200 day simple moving average is $2.92. Vigil Neuroscience has a 52 week low of $1.49 and a 52 week high of $6.06.

Analyst Ratings Changes

A number of brokerages have recently commented on VIGL. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. William Blair began coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an "outperform" rating for the company. HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Vigil Neuroscience in a report on Thursday, January 23rd. Wedbush boosted their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an "outperform" rating in a report on Friday, November 8th. Finally, JMP Securities restated a "market outperform" rating and set a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vigil Neuroscience has a consensus rating of "Buy" and an average target price of $19.75.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds have recently bought and sold shares of the company. abrdn plc purchased a new stake in shares of Vigil Neuroscience in the 3rd quarter valued at about $799,000. Geode Capital Management LLC grew its position in Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock worth $769,000 after purchasing an additional 66,712 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Vigil Neuroscience in the 3rd quarter worth $442,000. Walleye Capital LLC increased its stake in Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock worth $407,000 after buying an additional 92,217 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in Vigil Neuroscience by 7.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock worth $5,440,000 after purchasing an additional 115,000 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.